HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA In Brief

This article was originally published in The Rose Sheet

Executive Summary

OTC drug labeling: FDA's toll-free MedWatch number will be required on all non-monograph OTC drug products, effective April 22, 2005, agency announces. Published April 22 in the Federal Register, the proposal recommends the statement be placed in the "Warnings" section of the Drug Facts panel, under the "Stop Use and Ask a Doctor If" subheading. FDA is recommending that the side effects statement first direct consumers to consult a doctor for medical advice if side effects occur. The labeling addition is required under Best Pharmaceuticals for Children Act, which became law in 2002. The agency estimates 522 OTCs will be subject to the rule, and predicts OTC drug manufacturers will incur a one-time cost of $1.2 mil.-$3.7 mil., depending upon the number of affected SKUs...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel